Applied BioCode Corporation (6598.TW)

TWD 18.0

(-5.51%)

Total Liabilities Summary of Applied BioCode Corporation

Applied BioCode Corporation's latest annual total liabilities in 2023 was 332.21 Million TWD , down -16.19% from previous year.
Applied BioCode Corporation's latest quarterly total liabilities in 2024 Q2 was 348.97 Million TWD , up 1.42% from previous quarter.
Applied BioCode Corporation reported annual total liabilities of 396.38 Million TWD in 2022, up 241.68% from previous year.
Applied BioCode Corporation reported annual total liabilities of 116.01 Million TWD in 2021, down -17.27% from previous year.
Applied BioCode Corporation reported quarterly total liabilities of 344.08 Million TWD for 2024 Q1, up 3.57% from previous quarter.
Applied BioCode Corporation reported quarterly total liabilities of 332.21 Million TWD for 2023 Q4, down -24.01% from previous quarter.

Annual Total Liabilities Chart of Applied BioCode Corporation (2023 - 2012)

Historical Annual Total Liabilities of Applied BioCode Corporation (2023 - 2012)

Year	Total Liabilities	Total Liabilities Growth
2023	332.21 Million TWD	-16.19%
2022	396.38 Million TWD	241.68%
2021	116.01 Million TWD	-17.27%
2020	140.22 Million TWD	-25.55%
2019	188.35 Million TWD	131.55%
2018	81.34 Million TWD	34.89%
2017	60.3 Million TWD	17.84%
2016	51.17 Million TWD	25.81%
2015	40.67 Million TWD	4.37%
2014	38.97 Million TWD	64.93%
2013	23.63 Million TWD	18.18%
2012	19.99 Million TWD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	348.97 Million TWD	1.42%
2024 Q1	344.08 Million TWD	3.57%
2023 Q4	332.21 Million TWD	-24.01%
2023 FY	332.21 Million TWD	-16.19%
2023 Q2	411.98 Million TWD	6.88%
2023 Q3	437.17 Million TWD	6.12%
2023 Q1	385.45 Million TWD	-2.76%
2022 Q1	124.32 Million TWD	7.17%
2022 Q2	405.46 Million TWD	226.13%
2022 Q4	396.38 Million TWD	-6.71%
2022 Q3	424.88 Million TWD	4.79%
2022 FY	396.38 Million TWD	241.68%
2021 FY	116.01 Million TWD	-17.27%
2021 Q3	129.33 Million TWD	2.22%
2021 Q4	116.01 Million TWD	-10.3%
2021 Q1	134.82 Million TWD	-3.85%
2021 Q2	126.52 Million TWD	-6.16%
2020 Q1	184.13 Million TWD	-2.24%
2020 Q2	169.94 Million TWD	-7.7%
2020 Q3	182.58 Million TWD	7.43%
2020 Q4	140.22 Million TWD	-23.2%
2020 FY	140.22 Million TWD	-25.55%
2019 Q1	- TWD	-100.0%
2019 FY	188.35 Million TWD	131.55%
2019 Q3	344.84 Million TWD	25.33%
2019 Q2	275.15 Million TWD	0.0%
2019 Q4	188.35 Million TWD	-45.38%
2018 Q2	83.08 Million TWD	28.95%
2018 FY	81.34 Million TWD	34.89%
2018 Q4	81.34 Million TWD	0.0%
2018 Q1	64.43 Million TWD	6.84%
2017 FY	60.3 Million TWD	17.84%
2017 Q2	62.93 Million TWD	21.8%
2017 Q1	51.67 Million TWD	0.97%
2017 Q3	36.86 Million TWD	-41.43%
2017 Q4	60.3 Million TWD	63.59%
2016 Q2	49.75 Million TWD	0.0%
2016 Q4	51.17 Million TWD	0.0%
2016 FY	51.17 Million TWD	25.81%
2015 FY	40.67 Million TWD	4.37%
2015 Q4	40.67 Million TWD	0.0%
2014 FY	38.97 Million TWD	64.93%
2013 FY	23.63 Million TWD	18.18%
2012 FY	19.99 Million TWD	0.0%

Peer Total Liabilities Comparison of Applied BioCode Corporation

Name	Total Liabilities	Total Liabilities Difference
Excelsior Medical Co., Ltd.	7.16 Billion TWD	95.365%
Apex Medical Corp.	883.97 Million TWD	62.418%
OK Biotech Co., Ltd.	672.26 Million TWD	50.582%